Rekha Hemrajani - 10 Sep 2025 Form 4 Insider Report for LB PHARMACEUTICALS INC (LBRX)

Role
Director
Signature
/s/ Marc Panoff, Attorney-in-Fact
Issuer symbol
LBRX
Transactions as of
10 Sep 2025
Transactions value $
$0
Form type
4
Filing time
12 Sep 2025, 18:25:23 UTC
Previous filing
27 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hemrajani Rekha Director C/O LB PHARMACEUTICALS INC, ONE PENNSYLVANIA PLAZA, SUITE 1025, NEW YORK /s/ Marc Panoff, Attorney-in-Fact 12 Sep 2025 0001771213

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LBRX Stock Option (Right to Buy) Award $0 +22.4K $0.00 22.4K 10 Sep 2025 Common Stock 22.4K $15.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award shall vest in three (3) equal annual installments on September 10, 2026, September 10, 2027 and September 10, 2028, subject to the Reporting Person's continuous service through such vesting date.